Terns Pharmaceuticals Announces Upcoming Presentation
FOSTER CITY, Calif. — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a trailblazer in the biopharmaceutical sector, is excited to announce its participation in a prestigious healthcare conference. This conference serves as an important platform for Terns, where it will showcase its latest innovations in small-molecule product candidates that target significant health challenges, particularly in oncology and obesity.
Details of the Presentation
The 43rd Annual J.P. Morgan Healthcare Conference is just around the corner, taking place on January 15. Terns’ management team will take the stage at 4:30 p.m. PT to share insights about their cutting-edge projects and research work. This event is renowned in the industry, attracting numerous investors and professionals eager to learn about breakthroughs in health and medicine.
What to Expect from Terns
During the presentation, Terns Pharmaceuticals is expected to elaborate on its diverse pipeline, which encompasses three clinical-stage development programs. These include an allosteric BCR-ABL inhibitor designed to combat specific cancer types, a small-molecule GLP-1 receptor agonist aimed at treating obesity, and a THR-? agonist that shows promise in metabolic disorders. There’s also a focus on a preclinical GIPR modulator disco, where Terns is prioritizing the nomination of an antagonist candidate.
Accessing the Live Webcast
For those unable to attend the event in person, Terns Pharmaceuticals will offer a live webcast of the presentation, ensuring that interested parties can stay informed. This will be accessible on the investor relations section of the Terns Pharmaceuticals website. Additionally, a replay of the presentation will be made available, allowing for viewing at convenience for up to 30 days post-event. This initiative underlines Terns’ commitment to transparency and keeping stakeholders updated.
About Terns Pharmaceuticals
Terns Pharmaceuticals is recognized for its unyielding dedication to developing innovative therapies for critical diseases. By focusing on small-molecule therapies, Terns aims to effect meaningful change in the treatment landscape of serious conditions. The company operates out of Foster City, California, and specializes in addressing diseases that have a profound impact on patient health and quality of life.
Engagement with Stakeholders
Terns Pharmaceuticals values its relationship with investors and the media, understanding the pivotal role they play in the company's growth and outreach. For inquiries regarding investor relations, you can contact Justin Ng. Media representatives can reach out to Jenna Urban at Berry & Company Public Relations. Both are ready to provide timely information and updates on Terns’ endeavors and initiatives.
Frequently Asked Questions
What is Terns Pharmaceuticals focusing on during the conference?
Terns will present its innovative developments aimed at treating serious diseases such as oncology and obesity.
How can I watch the presentation?
The presentation can be accessed via live webcast on the Terns Pharmaceuticals investor relations website.
What products is Terns currently developing?
Terns is developing an allosteric BCR-ABL inhibitor, a GLP-1 receptor agonist, and a THR-? agonist, among others.
Where is Terns Pharmaceuticals headquartered?
Terns Pharmaceuticals is based in Foster City, California.
Who can I contact for more information?
For investor inquiries, contact Justin Ng; for media questions, contact Jenna Urban at Berry & Company Public Relations.
